Increase In Uric Acid Levels Research Articles

Association of Increase in Uric Acid Level With Worsening Renal Function in Patients With Congestive Heart Failure

Background: Occasionally, increase in serum uric acid (SUA) levels during hospitalization was observed in patients with congestive heart failure (HF), and hyperuricemia is known as an independent predictor of adverse outcomes. In this study, we investigated the factors associated with SUA elevation during hospitalization in HF patients. Methods and Results: We enrolled 98 patients (80 ± 8.8 years, 45 male) hospitalized for congestive HF with normal SUA (<7.0 mg/dL). Blood test was performed on admission (1st measurement) and two weeks later (2nd measurement). Patients were divided into two groups according to the presence of hyperuricemia (SUA > 7.0 mg/dL) at 2nd measurement: high SUA group (n = 28) and normal SUA group (n = 70). No difference was found in the baseline characteristics, such as coronary risk factors, NT-proBNP and renal function between the two groups. However, change in estimated glomerular filtration rate (eGFR) was significantly greater in hyperuricemia group (−8.3 vs −3.8 mL/min/1.73 m2, P = .037). Interestingly, NT-proBNP level was unchangeable between two measurements in high SUA group (5314 to 4540 pg/mL, ns), whereas NT-proBNP was significantly reduced in normal SUA group (2983 to 1966 pg/mL, P = .037). Conclusion: An increase in the SUA levels during hospitalization was associated with worsening renal function. Our study suggested that variation of SUA levels is also important predictor of clinical outcomes in patients with HF.

The Impact of Blood Pressure and Visceral Adiposity on the Association of Serum Uric Acid With Albuminuria in Adults Without Full Metabolic Syndrome

The impact of metabolic phenotypes on the association of uricemia with urinary albumin/creatinine ratio (uACR) remains unresolved. We evaluated the association between serum uric acid and uACR in persons with 0, and 1-2 metabolic syndrome (MetS) components and determined the modification effects of visceral adiposity index (VAI), mean arterial pressure (MAP), and fasting glucose on this association. Using data from a cross-sectional survey of a representative Czech population aged 25-64 years (n = 3612), we analyzed 1,832 persons without decreased glomerular filtration rate <60ml/min/1.73 m2, diabetes, and MetS. MetS components were defined using the joint statement of the leading societies. Of the 1,832 selected participants, 64.1% (n = 1174) presented with 1-2 MetS components (age 46.3±11.2; men 51.7%), whereas 35.9% (n = 658) were free of any component (age 39.4±10.0; men 34.2 %). In fully adjusted multiple linear regression models for uricemia, uACR was an independent factor for increase in uric acid levels only in persons with 1-2 MetS components (standardized beta (Sβ) 0.048; P = 0.024); however, not in those without any component (Sβ 0.030; P = 0.264). Uric acid levels increased by the interaction of uACR with VAI (Sβ 0.06; P = 0.012), and of uACR with MAP (Sβ 0.05; P = 0.009). Finally, the association of uACR with uricemia was confined to persons whose VAI together with MAP were ≥the median of 1.35 and 98mm Hg, respectively (Sβ 0.190; P < 0.001). We demonstrated a strong modification effect of VAI and MAP on the association between uACR and uricemia, which suggests obesity-related hypertension as the underlying mechanism.

ANTIOXIDANT EFFECT OF AQUEOUS SEED EXTRACT OF AFRAMOMUM SCEPTRUM (KSCHUM) ON BRAIN AND KIDNEY OF MALARIA INFESTED MICE

The present study investigated the antioxidant effect of aqueous seed extract of Aframomum sceptrum against oxidative stress induced in Plasmodium berghei infected mice. Adult-albino mice (male), weighing 15-25 g, were inoculated intraperitorically with 0.1 ml parasitized blood suspension. A. sceptrum extract was orally administered at different dosages (250 and 350 mg/kgb.wt), daily to both normal and malaria induced mice for a period of 4 days. There was increase in uric acid level and decrease in albumin, respectively, in brain and kidney in malaria mice compared to normal control. After treating with A. sceptrum, a significant (p<0.05) decrease and increase in uric acid and albumin levels, respectively, in the parasitized mice’s brain and kidney were observed compared to the parasitized control. The results suggest that A. sceptrum extract may contribute to the prevention of oxidative damage caused by malaria.

Disruption, but not overexpression of urate oxidase alters susceptibility to pentylenetetrazole- and pilocarpine-induced seizures in mice.

There is a continuous drive to find new, improved therapies that have a different mechanism of action in order to help diminish the sizable percentage of persons with pharmacoresistant epilepsy. Uric acid is increasingly recognized as contributing to the pathophysiology of multiple disorders, and there are indications that uric acid might play a role in epileptic mechanisms. Nevertheless, studies that directly investigate its involvement are lacking. In this study we assessed the susceptibility to pentylenetetrazole- and pilocarpine-induced seizures in mice with genetically altered uric acid levels by targeting urate oxidase, which is the enzyme responsible for uric acid breakdown. We found that although disruption of urate oxidase resulted in a decreased susceptibility to all behavioral end points in both seizure models, overexpression did not result in any alterations when compared to their wild-type littermates. Our results suggest that a chronic increase in uric acid levels may result in decreased brain excitability.

Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study

Background and aimsNew antithrombotic therapies have significantly improved the outcomes of patients with acute coronary syndrome (ACS), where the introduction of ticagrelor has provided the greatest mortality benefits. However, ticagrelor treatment has been associated with a potential increase in the serum uric acid (SUA) levels, which may influence endothelial dysfunction and prothrombotic status, thereby affecting the risk of acute cardiovascular events in patients requiring dual antiplatelet therapy (DAPT). The present study aimed to compare the impact of antiplatelet agents such as ticagrelor or clopidogrel on SUA levels and their effect on platelet reactivity. Methods and resultsWe included patients admitted for ACS or elective percutaneous coronary intervention (PCI) and discharged with ASA (acetylsalicylic acid; 100–160 mg) and clopidogrel (75 mg) or ticagrelor (90 mg twice a day). Chemistry was assessed at admission (baseline) and after a 30–90-day period of DAPT (together with platelet reactivity). The absolute and percentage variations of SUA after DAPT introduction were considered. Multiple-electrode aggregometry was used to assess platelet function.A total of 378 patients were enrolled, with 145 treated with aspirin and clopidogrel (AC) and 233 with aspirin and ticagrelor (AT). The AC patients were older (p = 0.003) and more often showed elective PCI as an indication to DAPT (<0.001); they received chronic therapy with ARB (angiotensin II receptor blocker; p = 0.001), nitrates (p = 0.044), CCB (calcium channel blocker; p = 0.005) and diuretics (p = 0.044). The AT patients displayed a higher percentage of ACS diagnosis (p < 0.001) and received chronic therapy with ACE (angiotensin-converting enzyme) inhibitors (p = 0.001), beta blockers (p = 0.001) and statins (p = 0.013).The AC patients displayed higher platelet reactivity at COL (collagen) test, ASPI test and ADP (adenosine diphosphate) test (p = 0.03, 0.001 and <0.001, respectively) and a higher percentage of HRPR (high residual platelet reactivity) in the ADP test (p = 0.001).No difference was found in the baseline uric acid and creatinine levels between AC and AT patients. At 30–90 days, a significant absolute and percentage increase in the SUA levels was found in AT as compared to AC patients (0.204 mg/dl vs. −0.165 mg/dl, p = 0.034; 6.26% vs. −0.005%, p = 0.018, respectively). Results were not influenced by variations in renal function. At multivariate analysis, in fact, ticagrelor therapy emerged as an independent predictor of increase in the uric acid levels (odds ratio (OR; 95% confidence interval (CI)) = 2.79 (1.66–4.67), p < 0.001). However, the variation in the SUA levels did not affect platelet reactivity or HRPR in both AC and AT patients. ConclusionAn increase in the SUA levels at 30–90 days was observed in patients receiving chronic DAPT with ticagrelor, but not clopidogrel treatment. However, the changes in the SUA levels do not influence platelet aggregation.

Blood biochemistry responses of ducks infected with a velogenic Newcastle disease virus

This study investigated the blood biochemistry responses of Pekin ducks (Anas platyrhynchos domesticus) experimentally infected with a velogenic Newcastle disease virus (NDV), KUDU 113 strain. One hundred ducklings were used for the study. The ducks were obtained at a week old and randomly divided into three groups. One group was vaccinated against NDV with La Sota vaccine at 3 weeks of age. The vaccinated and unvaccinated groups of 30 ducks each were subsequently challenged with the velogenic NDV after 6 weeks of brooding, while the control group of 40 ducks was not vaccinated and not challenged. Blood samples were randomly collected from five birds in each group, allowed for about 30 min to clot, centrifuged, and serum harvested. Blood biochemistry determinations were carried out at 3-day intervals from days 0 to 15 and day 21 post inoculation (PI). The results showed a significant increase in albumin on day 6 PI and total protein and globulin on day 9 PI and a significant increase in uric acid levels in the infected groups when compared with the unvaccinated uninfected controls from days 3 to 12 PI. The significant increase in uric acid level in both the vaccinated infected and unvaccinated infected groups in the absence of any overt clinical sign is noteworthy as uric acid determination can be a useful screening tool for detection of the velogenic NDV in apparently healthy ducks before they constitute a risk to in-contact poultry or spread to the environment.

Changing of Uric Acid Levels by Age and Sex in Patients with Diabetes Mellitus

Objective: We examined the association between uric acid and glycemic status by the aspects of age and sex. Methods: The retrospective was performed study at Okmeydani Educate and Research Hospital. All data were obtained from the patient records. Only one sample of HbA1c or glucose measurement within a year was included. To evaluate the pattern of glucose control, we categorized the patients according to HbA1c levels and grouped them according to a range of values. HbA1c was measured by high performance liquid chromatography, routine biochemistry parameters were determined by photometric method. Results: Serum uric acid levels showed an increasing trend with the age in female group and this trend became significant after 30 years old (p<0.001). The significant effect of HbA1c and gender on uric acid levels were determined in the subjects having no renal failure. There was a significant increase of uric acid levels in prediabetics than normal group and decrease in unregulated diabetics. But in both sex groups the pattern of changing was different. Conclusion: In conclusion, we found that age is an important factor examining the serum uric acid levels of female subjects. The peak values of serum uric acid were detected in prediabetic group in males but in females this peak point was diabetic group. J Clin Exp Invest 2016; 7 (1): 1-6 Key words: Diabetes mellitus, uric acid, age, gender

Changing of Uric Acid Levels by Age and Sex in Patients with Diabetes Mellitus

Objective: We examined the association between uric acid and glycemic status by the aspects of age and sex. Methods: The retrospective was performed study at Okmeydani Educate and Research Hospital. All data were obtained from the patient records. Only one sample of HbA1c or glucose measurement within a year was included. To evaluate the pattern of glucose control, we categorized the patients according to HbA1c levels and grouped them according to a range of values. HbA1c was measured by high performance liquid chromatography, routine biochemistry parameters were determined by photometric method. Results: Serum uric acid levels showed an increasing trend with the age in female group and this trend became significant after 30 years old (p<0.001). The significant effect of HbA1c and gender on uric acid levels were determined in the subjects having no renal failure. There was a significant increase of uric acid levels in prediabetics than normal group and decrease in unregulated diabetics. But in both sex groups the pattern of changing was different. Conclusion: In conclusion, we found that age is an important factor examining the serum uric acid levels of female subjects. The peak values of serum uric acid were detected in prediabetic group in males but in females this peak point was diabetic group. J Clin Exp Invest 2016; 7 (1): 1-6 Key words: Diabetes mellitus, uric acid, age, gender

Migratory refueling affects non-enzymatic antioxidant capacity, but does not increase lipid peroxidation

All aerobic organisms are to some degree affected by oxidative stress, which is an imbalance between pro-oxidants and antioxidants in favor of the former. Pro-oxidants can damage DNA, proteins and lipids, and as such oxidative stress can carry considerably fitness costs. In mammals excessive calorie intake is a known cause of oxidative stress. We investigated whether in migrant birds, which typically engage in over-eating in between flights (refueling), high food intake causes oxidative stress. In an experiment we compared levels of plasmatic total non-enzymatic antioxidant capacity (AOX) and oxidative damage (lipid peroxidation) between migrants repeatedly fasted and refed (simulating the flight-refuel cycle of wild migrants), and migrants on ad libitum food. We found that refueling increased AOX, an effect mainly attributable to an increase in uric acid level, an antioxidant that is produced during protein metabolism. Accordingly, variation in AOX was mainly explained by the refueling birds' food intake. However, food intake in migrants on ad libitum food did not explain any variation in AOX. Refueling did not affect lipid peroxidation, nor were its levels explained by food intake. We propose that over-eating migrants retain uric acid, which might be a very low cost mechanism to forego oxidative damage.

Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer.

Bevacizumab is a monoclonal antibody which is a vascular endothelial growth factor inhibitor. It obscures vascularization of tumor tissue and damages intratumoral microcirculation. The damaged intratumoral microcirculation leads to tissue hypoxia and results in increase of uric acid level. The main aim of our study was to investigate the relationship between uric acid change and response to bevacizumab therapy. This study included a total of 158 patients with metastatic colorectal cancer who had received bevacizumab therapy. The number of male patients was 100 (63.3%) while female patients number was 58 (37.7%). The median age was 61 (29-83). There was relationship between increase of uric acid level of third month uric acid level and stable disease (p<0.001). There was a significant overall survival increased in the group with increased uric acid level (p<0.001). The decline of CEA level was related to uric acid level (p<0.022). In conclusion, this study is the first showing significant increases of serum uric acid in patients with metastatic colorectal cancer who favorably responded to chemotherapy with bevacizumab. But further studies are justified to test whether monitoring uric acid levels might predict clinical outcomes of patients with metastatic colorectal cancer.

Relationship between Uric Acid and Endothelial Function in Hypertensive Patients with Metabolic Syndrome

Aim: To investigate the association between uric acid (UA) and endothelial function in Chinese hypertensive patients with Metabolic Syndrome (MS). Methods: 615 hypertensive patients were enrolled, all hypertensives were divided into two groups: hypertensives with MS (MS group, n=239) and hypertensives without MS (NMS group, n=376). 87 age- and sex-matched normotensives served as controls (NC group). Flow-mediated (endothelium-dependent) dilatations (FMD), nitroglycerin-induced (endothelium-independent) dilatation (EID) in the brachial artery were assessed by highresolution ultrasonography. UA was detected by urease indophenol. Results: A trend of increase in UA concentration was found among NC, NMS and MS group ((323.77 ± 104.49) μmol/l vs. (353.63 ± 92.83) μmol/l vs. (390.90 ± 101.42) μmol/l, p<0.001). There was a significant difference in FMD (control: (12.03 ± 4.51)% vs. NMS:(8.98 ± 4.32)% vs. MS:(8.23 ± 4.58)%, p<0.001) among groups. After stratification of gender, lower FMD was only seen in male hypertensives with MS accompanied by hyperuricemia <60 years old ((9.98 ± 5.78)% vs (7.12 ± 4.49)%, p<0.05); Pearson correlation analysis showed that the FMD was negatively correlated with UA (r=-0.314, p<0.01); Finally, logistic regression analysis showed that a 50 μmol/L increase in UA levels carried a 41.1% higher risk for endothelial dysfunction in this cohort. Conclusions: A higher UA level is related to poorer endothelial function in hypertensives with MS. Increased UA can be used as an alternative indicator for monitoring endothelial function and preventing vascular damage in male hypertensives with MS aged less than 60 years old.

Effects of Aquilaria Crassna on Xanthine Oxidase Activity In Vitro and Hyperuricemic Mice

Antihyperuricemic effect Aquilaria crassna leaf extract has been commercially advertised to markedly reduce uric acid level after drinking with hot water in Thailand, whereas its experimental evidence has not been published yet. The present study was therefore conducted to investigate pharmacological activities of the water extract of A. crassna leaves, focusing on its inhibitory effect on xanthine oxidase activity in vitro and antihyperuricemic effect in plasma uric acid level in oxonate-induced hyperuricemic mice. Moreover, the residual xanthine oxidase inhibitory effect in the liver of mice treated with the extract was also determined. We found that A. crassna inhibited xanthine oxidase activity in with IC50 of 1.35±0.03 mg/ml. Lineweaver- Burk analysis showed that the inhibition of xanthine oxidase was non-competitive with Ki of 1.72 mg/ml. Oral administration of 3000 mg/kg of A. crassna extract significantly prevented the increase of uric acid level induced by potassium oxonate in mice, however, the lower doses (500 and 1000 mg/kg) showed no effect. Livers of mice treated with the extract at the doses of 1000 and 3000 mg/kg significantly decreased the production of uric acid through inhibition on xanthine oxidase activity approximately 47.2% and 63.6%, as compared with untreated hyperuricemic mice (P<0.01). However, the concentrations of A. crassna of which exhibit antihyperuricemic effect observed in the study were much higher than that of recommend dosage written in the commercial, therefore, we concluded that A. crassna leaves extract could not inhibit xanthine oxidase activity and the effect on urate excretion in the kidney by long term administration the extract is further needed.

Hyperuricemia and Its Prognostic Value in Patients with Rheumatic Heart Disease

BACKGROUND: Hyperuricemia has recently been linked to cardiovascular diseases, such as coronary artery disease and heart failure, as a marker of disease activity for prognostication. However, there are no studies correlating uric acid levels with heart failure among patients with rheumatic heart disease (RHD). METHODOLOGY: This is a prospective cohort study correlating the increase in uric acid levels with the development of heart failure symptoms in patients with RHD. Fifty-one subjects with RHD and with good functional capacity (New York Heart Association [NYHA] Class I) were included in the study. The subjects were followed up for one year, in which 24 subjects fulfilled the Framingham criteria for heart failure and 27 remained in NYHA Class I. RESULTS:Mean baseline uric acid levels were similar between the two groups (heart failure 390±82 umol/L; no heart failure 388±134 umol/L; p=0.964). The mean difference between the baseline and endpoint serum uric acid levels in those without heart failure was not statistically significant (baseline 388±134 umol/L vs. endpoint 391±134 umol/L; p=0.77). In those who developed heart failure, the mean endpoint serum uric acid levels became significantly higher from baseline (baseline 390±82 umol/L vs. endpoint 437±106umol/L; p=0.0007). There was a significantly greater increase in serum uric acid levels in patients who eventually developed heart failure symptoms (heart failure 47.1±59.1 umol/L vs. no heart failure 2.6±46 umol/L; p=0.004). An increase in serum uric acid level by 30 umol/L from baseline had a sensitivity of 70.83% and a specificity of 74.07% for predicting the occurrence of heart failure symptoms. CONCLUSION: Increasing serum uric acid levels are associated with the development of heart failure symptoms in patients with RHD. KEYWORDS: rheumatic heart disease, mitral stenosis, mitral regurgitation, aortic stenosis, aortic regurgitation, congestive heart failure, uric acid, hyperuricemia

Uric acid and xanthine oxidase in heart failure - Emerging data and therapeutic implications.

The role of hyperuricaemia as cardiovascular risk factor has exhaustingly been debated for decades. While the association of elevated uric acid (UA) levels with increased mortality risk as convincingly been shown, the question whether UA is independently predictive of just a related effect within a more complex risk factor profile (including metabolic, inflammatory and haemodynamic risk factors) is still a matter of dispute. In heart failure the independent prognostic and functional impact of elevated UA has not only been shown but also the pathophysiologic mechanism(s) and the potential of targeted therapeutic interventions have been investigated in some detail. The emerging picture suggests the increased activity of the enzyme xanthine oxidase (XO) with corresponding increased production of free oxygen radical (ROS) as a main underlying principle with the resulting increase in UA levels being mostly a marker of this up-regulated pathway. While this concept will not diminish the value of UA as a prognostic marker, it provides the basis for a novel metabolic treatment option and the means to identify those patients most eligible for this tailored therapy. This review will summarize the recent evidence on XO as a novel and promising therapeutic target in heart failure.

0098 : Uric acid predict clinical outcomes in heart failure

Heart failure (HF) has become a major epidemic and a significant public health problem, with considerable morbidity and mortality. Uric acid (UA) levels are frequently increased in patients with heart failure (HF), and may be an indicator of a poor prognosis and an innovative target for treatment. We evaluated the prognostic effect of UA on clinical outcome in patients with HF. In addition, we looked at the relation of UA to echocardiographic parameters in a subset of these patients. Totally 309 consecutive patients with chronic heart failure symptomatic class II, III, or IV were retrospectively studied. Clinical, electrocardiographic, echocardiographic and biological data were investigated. 84% of the patients had elevated UA (>70mg/L in men and >60mg/l in women). We divided patients on 2 groups: group 1 with hyperuricemia and group 2 without hyperuricemia. Mean UA levels were 71,4mg/l in group 1 and 42,2mg/l in group 2. Male sex, diabetes mellitus, hyperlipidemia, and ischemic heart disease were associated with higher UA levels. Increased urea and creatinine were also associated with higher UA levels, whereas reduced estimated glomerular filtration rate, hyponatremia treatment with furosemide were seen with higher UA levels. An increase in UA levels was a predictor of increased cardiac hospitalizations (p= 0.0001) and mortality (p<0.00039). Echocardiographic data demonstrated a significant correlation between UA levels and E/A ratio, a marker of diastolic dysfunction (p<0.0001). Increased UA level was independent predictor of increased morbidity and mortality in a cohort of ambulatory patients with chronic heart failure.

The relationship of serum uric acid with risk factors of metabolic syndrome in Uygur in Xinjiang

Objective To analyze the distribution characteristics of blood uric acid and its relationship with the risk factors of metabolic syndrome in Uygur.Methods The questionnaire,anthropometric measurements,and biochemical detection were carried out in 4 428 healthy Uygur subjects in Xinjiang Urumqi and Kashi hospitals.Results (1) The prevalences of hyperuricemia and metabolic syndrome were 21.3 ％ and 8.2％,respectively.With the increased blood uric acid level,the incidences of coronary heart disease,hyperglycemia,hypertension,central obesity,and dyslipidemia were raised.Blood pressure,blood glucose,HbA1c,triglyceride,total cholesterol,apolipoprotein A,low density lipoprotein-cholesterol,body mass index (BMI),and waist to hip ratio (WHR) were increased with increased uric acid level,while high density lipoprotein-cholesterol was decreased.(2) The incidence of hyperuricemia was increased further when the number of metabolic syndrome components was accumulated (P＜0.01).With the increase of uric acid level,the prevalence of metablic syndrome gradually raised (P＜0.01).(3) Multiple logistic regression analysis showed that WHR (OR =7.639,95 ％ CI 1.744-33.466),coronary heart disease (OR =2.784,95 ％ CI 1.718-4.510),hyperuricemia (OR =2.155,95 ％ CI 1.457-3.188),smoking (OR =1.437,95％ CI 1.071-1.927),family history of metabolic diseases (OR =1.333,95％ CI 1.044-1.703),occupational pressure (OR =1.290,95 ％ CI1.021-1.631),and BMI (OR =1.146,95 ％ CI 1.112-1.181) were the risk factors of metabolic syndrome.Exercise (OR=0.472,95％ CI0.370-0.604) and low salt diet (OR=0.793,95％ CI0.662-0.949) were the protective factors.Conclusion Serum uric acid level is correlated with a variety of metabolic parameters.With the increased uric acid level,the risk of multiple metabolic abnormality was increased.Comprehensive prevention and control should be taken for the reduction of the risk factors and much attention should be paid to the adverse effects of hyperuricemia. Key words: Uric acid; Metabolic syndrome; Risk factor; Uygur; Association

SAT0517 Prognostic Value of Long-Term Cumulative Uric Acid Level on Cardiovascular Diseases in Gout Patients with Treatment

BackgroundThe role of serum uric acid as an independent risk factor for cardiovascular disease (CVD) remains unclear, although hyperuricemia is associated with CVD such as ischemic heart diseases (IHD), cerebrovascular...

Association between serum uric acid level and microalbuminuria to chronic vascular complications in Thai patients with type 2 diabetes

AimsTo investigate an association between serum uric acid/microalbuminuria and chronic micro/macro-vascular complications in type 2 diabetic patients. MethodsThis cross-sectional study enrolled 608 patients with type 2 diabetes. All subjects were examined and basic information on health of the subjects was recorded for inclusion criteria. Several chemical parameters (fasting plasma glucose, triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, uric acid, and microalbuminuria), and related chronic vascular complications were measured and recorded in data forms. ResultsLogistic regressions were used to analyse odds ratios between uric acid/microalbuminuria levels and several chronic vascular complications. Prevalence of chronic vascular complications in T2DM patients, namely coronary arterial disease, cerebrovascular disease, diabetic nephropathy, diabetic retinopathy, and diabetic peripheral neuropathy was significantly correlated with increase of uric acid level [2.29 (1.01–5.2), 16.01 (4.74–54.09), 9.99 (4.4–22.8), 4.43 (1.3–15.1), 4.37 (1.5–12.9)], and of microalbuminuria level [7.0 (3.6–13.8), 3.2 (1.2–8.7), NA, 14.7 (5.1–42.7), 7.2 (2.9–17.7)]. ConclusionBoth elevated uric acid and microalbuminuria levels were significantly associated with diabetic chronic micro/macro-vascular complications. Monitoring of uric acid and microalbuminuria levels provides a predictive value for a presence of chronic micro/macro-vascular complications in patients with type 2 diabetes.

FRI0388 Patterns of compliance to allopurinol in “real life population” – is everything crystal clear?

BackgroundGout is a chronic crystal induced arthritis caused by the precipitation of monosodium urate crystals in the joints leading to inflammation and pain. Therapy includes non-steroidal anti-inflammatory drugs, steroids, allopurinol,...

Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricaemia

We report the case of a 36-year-old man with psoriatic arthritis and miliary tuberculosis, whose serum uric acid (SUA) level increased after the initiation of antituberculosis treatment, which included pyrazinamide. Most strikingly and paradoxically, the patient's SUA level increased after treatment with allopurinol. On cessation of allopurinol, his SUA level decreased substantially, and complete normalisation was observed following the discontinuation of pyrazinamide treatment.